Ridge Expansion in the Maxillary Aesthetic Zone Using Piezo-electric Surgery

NCT ID: NCT01796119

Last Updated: 2015-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this split-mouth controlled study, implants placed using the alveolar ridge expansion technique will be compared to those placed in native bone with sufficient horizontal bone width.

The Piezosurgery device and Bone expanders (Mectron,Italy) will be employed in an alveolar ridge expansion technique.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The success rate of endosseous implant placement in native bone has been proven to be highly predictable. Reliable long term result requires sufficient bone thickness surrounding the implant's body. This is especially true in the maxillary aesthetic zone where buccal bone thickness of 2mm or more is necessary to prevent loss of buccal bone margin and maintain the integrity of the gingival architecture.

Ridge expansion technique, an alternative to bone graft, widens the alveolar ridge prior to implant placement, thus permits the preservation of buccal and lingual bone thickness.

Narrow atrophy edentulous alveolar ridges (study site) in the maxillary aesthetic zone will be split lengthwise using piezo-electric surgery (Piezosurgery, Mectron, USA). The prepared osteotomy will subsequently be expanded using threaded osteotomes (Bone Expanders, Mectron, Italy). Implants will immediately be inserted in the prepared osteotomy. In the edentulous alveolar ridges with sufficient thickness (controlled site) in the maxillary aesthetic zone, implants will be placed directly using conventional drilling technique. Outcome measures will be compared.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tooth Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ridge Splitting

Dental implants placed using ridge splitting technique. To measure the horizontal bone width before and after implant insertion and 6 months post-op.

To measure BLI measured using PA radiographs taken immediately and 6 months post-op.

To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.

To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length.

Group Type EXPERIMENTAL

Ridge Splitting

Intervention Type PROCEDURE

To measure the horizontal bone width before and after implant insertion and 6 months post-op.

To measure BLI measured using PA radiographs taken immediately and 6 months post-op.

To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.

To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length.

Implants placed using drilling technique

Dental implants placed in the ridge with sufficient thickness using drilling technique.

To measure the horizontal bone width before and after implant insertion and 6 months post-op.

To measure BLI measured using PA radiographs taken immediately and 6 months post-op.

To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.

To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length.

Group Type ACTIVE_COMPARATOR

Implants placed using drilling technique

Intervention Type PROCEDURE

To measure the horizontal bone width before and after implant insertion and 6 months post-op.

To measure BLI measured using PA radiographs taken immediately and 6 months post-op.

To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.

To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ridge Splitting

To measure the horizontal bone width before and after implant insertion and 6 months post-op.

To measure BLI measured using PA radiographs taken immediately and 6 months post-op.

To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.

To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length.

Intervention Type PROCEDURE

Implants placed using drilling technique

To measure the horizontal bone width before and after implant insertion and 6 months post-op.

To measure BLI measured using PA radiographs taken immediately and 6 months post-op.

To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.

To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 18 years of age
* Systemically healthy
* Implant therapy will be the elective treatment option.
* The alveolar ridge thickness will be insufficient to receive implant of 3.5-4.3mm in diameter.
* The ridge width will be at least 4mm
* Implants will be placed in the maxillary edentulous ridge from second premolar to the opposite second premolar.
* There will be a second edentulous ridge in the same individual's mouth that serves as control site. The crest of this site will be at least 5.5mm wide, sufficient to receive an implant of 3.5-4.3 mm in diameter.
* Demonstrated ability to maintain oral hygiene
* Willingness and ability to commit to follow-up
* Able to understand study procedure and provide signed informed consent.
* In order to ensure optimal efficacy of the methods used to reduce the risk of pregnancy in female subjects and potential harm to a fetus, contraceptive measures are required in order to participate in the Study, as follows: hormonal methods and the IUD must be in used at least 30 days prior to Study drug administration; that barrier methods must be use in used at least 15 days prior to Study drug administration; that vasectomy must be completed 3 months prior to first Study drug administration; or in the alternative that a 0 sperm count will suffice.

Exclusion Criteria

* Extreme alveolar ridge atrophy with no cancellous bone between the buccal and palatal cortical plates
* Extensive vertical ridge resorption which requires vertical augmentation
* Uncontrolled periodontal disease.
* Need of sinus lift procedures in the site of intended implant placement.
* Recent febrile illness (within 6 months) that precludes or delays participation
* Wearers of pacemaker.
* Severe renal or liver diseases
* History of radiotherapy of the head and neck region
* Chemotherapy for treatment of malignant tumors at the time of the study.
* Immuno-compromised patients
* Patients on IV bisphosphonates or on long term oral bisphosphonates for more than 3 years.
* Use of disallowed concomitant medications.
* Pregnancy or intending to conceive during the course of the Study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Goethe University

OTHER

Sponsor Role collaborator

Clinique Dentaire et d'implantologie Dr.Vinh Nguyen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Vinh Giap Nguyen, DDS

D.D.S.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vinh Nguyen, DDS.

Role: PRINCIPAL_INVESTIGATOR

Goethe University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinique Dentaire et d'implantology Dr. Vinh Nguyen

Brossard, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB1665

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

GBR and Autogenous Bone Chips
NCT03946020 COMPLETED NA